Taub Amy Forman
Advanced Dermatology, 275 Parkway Drive, Suite 521, Lincolnshire, IL 60069, USA.
J Drugs Dermatol. 2004 Jan-Feb;3(1 Suppl):S8-25.
Photodynamic therapy (PDT) uses a photosensitizer, light, and molecular oxygen to selectively kill cells. When localized in the target tissue, the photosensitizer is activated by light to produce oxygen intermediates that destroy target tissue cells. The easy access of skin to light-based therapy has led dermatologists to apply PDT to cutaneous disorders. In dermatology, PDT has been most successful in treating actinic keratoses, basal cell carcinoma, and Bowen's disease. The introduction of aminolevulinic acid, which does not make patients susceptible to phototoxicity for extended periods, has reduced morbidity associated with PDT. This has led to new interest in PDT not only for nonmelanoma skin cancer and premalignant lesions but also in the treatment of acne and as an adjuvant to photorejuvenation procedures. This review examines the historical roots of PDT and the research evaluating different light and laser sources as well as reports on new horizons for PDT in dermatology.
光动力疗法（PDT）利用一种光敏剂、光和分子氧来选择性地杀死细胞。当光敏剂定位在靶组织中时，它会被光激活，产生破坏靶组织细胞的氧中间体。皮肤易于接受基于光的治疗，这使得皮肤科医生将光动力疗法应用于皮肤疾病的治疗。在皮肤科领域，光动力疗法在治疗光化性角化病、基底细胞癌和鲍温病方面最为成功。氨基酮戊酸的引入，它不会使患者长期易发生光毒性，降低了与光动力疗法相关的发病率。这不仅引发了对光动力疗法治疗非黑素瘤皮肤癌和癌前病变的新兴趣，还激发了其在痤疮治疗以及作为光嫩肤程序辅助手段方面的新关注。这篇综述探讨了光动力疗法的历史根源、评估不同光源和激光源的研究，以及皮肤科光动力疗法新前景的相关报道。
